Hypomania associated with high dose ketamine treatment

Authors:

Abstract
For more than 50 years, pharmacotherapy for major depressive disorder (MDD) has narrowly focused on enhancing monoaminergic neurotransmission resulting in more than 30 FDA‐ approved treatments. In contrast, the glutamatergic, non‐competitive N‐methyl D‐aspartate (NMDA) receptor antagonist ketamine has been “repurposed” as a rapid acting antidepressant1; the enantiomer S‐ketamine, or esketamine, is now FDA‐approved for treatment resistant unipolar depression (TRD).